AstraZeneca
AZ’s triple therapy inhaler hits 8 out of 9 endpoints
January 26, 2018Medical Communications, Research and Development AstraZeneca, COPD, biotech, drugs, pharma, pharmaceutical
AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
AstraZeneca expands drug discovery collaboration with X-Chem
January 18, 2018Research and Development, Sales and Marketing AstraZeneca, X-Chem, pharma
AstraZeneca and X-Chem are to expand their existing drug discovery collaboration, it has emerged. The partnership marks the third agreement …
AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer
January 15, 2018Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma
The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …
AZ’s Fasenra approved in Europe as an add-on for severe eosinophilic asthma
January 11, 2018Research and Development AstraZeneca, European Commission, Fasenra, MedImmune, asthma, pharma
AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
AstraZeneca continues pivot to east with Chinese collaboration
November 27, 2017Medical Communications, Sales and Marketing AstraZeneca, biotech, drugs, pharma, pharmaceutical
It’s been a rocky year for AstraZeneca, it has scored some major successes yet its year has been marred by …
AZ partners with Combinations Alliance to test drug in cancer
November 24, 2017Medical Communications, Research and Development AstraZeneca, biotech, drugs, pharma, pharmaceutical
A clinical trial is to be launched to test AstraZeneca’s experimental drug, AZD1775, for the treatment of head and neck …
AstraZeneca’s Fasenra scores US approval in severe asthma
November 15, 2017Research and Development, Sales and Marketing AstraZeneca, Fasenra, MedImmune, asthma
AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra …
AstraZeneca asthma therapy tralokinumab flops at Phase 3
November 1, 2017Research and Development AstraZeneca, MedImmune, asthma, pharma
AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …
AstraZeneca licenses genetic disease drug to Mereo Biopharma for $5 million, becomes shareholder
October 30, 2017Sales and Marketing AstraZeneca, Mereo BioPharma, pharma
AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin deficiency, to Mereo Biopharma for …
AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide
October 24, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, GSK, GlaxoSmithKline, R&D, Roche, pwC
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 …
ADC Therapeutics brings in $200 million of financing
October 24, 2017Manufacturing and Production, Sales and Marketing ADC Therapeutics, AstraZeneca, biotech, drugs, pharma, pharmaceutical
ADC Therapeutics has won some serious financial support after its latest financing round managed to net the company $200 million. …
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours
October 17, 2017Manufacturing and Production, Research and Development AstraZeneca, Cancer, Chi-Med, lung cancer, pharma, savolitinib
AstraZeneca and its partner Hutchison China MedTech, also known as Chi-Med, have announced positive data for savolitinib in combination with …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
